V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016356 | 160019784 | null | 63.3 | Palliative (P) | 2018-06-07 | 2018-07-15 | PEMBROLIZUMAB | 02 | N | TRIAL | 100530545 |
| 160016361 | 160019785 | 1.62 | 65.2 | Palliative (P) | 2020-12-10 | 2022-02-11 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | N | EW EUROEWING 2012 ARM B VDC/IE | 101091128 |
| 160016366 | 160019786 | 1.77 | 72.4 | null | 2019-03-13 | 2019-03-17 | CYCLOPHOSPHAMIDE | 01 | null | STS RHABDO RMS 2005 VIN CYCLO | 101311932 |
| 160016368 | 160019787 | 1.67 | 25.8 | null | 2019-03-19 | 2019-03-19 | DACARBAZINE + GEMCITABINE | 02 | null | DACARBAZINE + GEMCITABINE | 101578769 |
| 160016388 | 160019788 | 1.65 | 7 | Palliative (P) | 2020-04-12 | 2020-04-12 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 101042391 |
| 160016409 | 160019789 | 1.76 | 84.6 | null | 2019-06-28 | 2019-06-28 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | null | DACARBAZINE | 101579720 |
| 160016429 | 160019790 | 0 | null | null | 2016-05-05 | 2017-08-04 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | null | IFOSFAMIDE | 100736808 |
| 160016440 | 160019791 | 1.86 | 63.9 | null | 2019-04-17 | 2019-04-29 | Olaparib | 02 | null | FLUOROURACIL + IRINOTECAN | 100907107 |
| 160016447 | 160019792 | 1.62 | 92.9 | Curative (C) | 2020-02-12 | 2020-02-12 | STS Rhabdomyosarcoma RMS 2005 VA | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101003237 |
| 160016467 | 160019793 | 0 | 19.1 | Curative (C) | 2019-01-09 | 2019-01-16 | Olaparib | 02 | N | BLEOMYCIN | 100434212 |
| 160016477 | 160019794 | null | 64.8 | 03 | 2021-03-07 | 2021-03-14 | IPM | N | N | AXITINIB | 101786150 |
| 160016479 | 160019795 | 1.7 | 46.6 | null | 2019-05-12 | 2019-08-11 | Cyclophosphamide + Topotecan | 02 | N | NOT MATCHED | 100294636 |
| 160016488 | 160019796 | 0 | 66.7 | Neo-adjuvant (N) | null | 2018-08-14 | LANREOTIDE | 01 | N | TEMOZOLOMIDE | 100949605 |
| 160016489 | 160019797 | 1.5 | 78.1 | Curative (C) | 2017-07-30 | 2017-09-03 | Gemcitabine day 1&8 | 02 | N | PEMETREXED | 100100749 |
| 160016503 | 160019798 | 1.82 | 48.6 | Curative (C) | 2017-07-15 | 2017-07-16 | Cisplatin + Liposomal Doxorubicin | 02 | N | EW EUROEWING 2012 ARM B VC | 101759217 |
| 160016526 | 160019799 | 0 | 38.6 | Palliative (P) | null | null | NB Rel CCLG guidelines Cyclo-Topotecan | 01 | N | DOXORUBICIN + IFOSFAMIDE | 101319145 |
| 160016540 | 160019801 | 0 | 17.6 | Neo-adjuvant (N) | 2021-07-18 | 2021-11-24 | null | 02 | N | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 101003034 |
| 160016547 | 160019802 | 1.72 | 24.75 | Curative (C) | 2019-07-22 | 2019-12-18 | EW EuroEwing 2012 Arm B VDC/IE | 02 | N | TRIAL | 100387025 |
| 160016557 | 160019803 | 0 | 121 | null | 2021-02-07 | 2021-02-19 | null | 02 | null | GEMCITABINE + TREOSULFAN | 100069644 |
| 160016584 | 160019804 | 0 | null | null | 2020-09-05 | 2020-09-17 | null | 02 | null | NB LOW/INTERMED RISK GUIDELINES CADO | 100622382 |
| 160016587 | 160019805 | 1.57 | 56.3 | Palliative (P) | null | 2022-02-18 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101439690 |
| 160016601 | 160019806 | 1 | 68.2 | Palliative (P) | 2017-09-29 | 2017-10-06 | Olaratumab | N | N | TRIAL | 101288706 |
| 160016613 | 160019807 | 1.58 | 999 | null | 2017-06-16 | 2017-08-01 | STS Rhabdo RMS 2005 Vin Cyclo | N | null | OLARATUMAB | 101487963 |
| 160016634 | 160019808 | 1.73 | 92.9 | Neo-adjuvant (N) | 2018-09-18 | 2018-09-18 | STS Rhabdomyosarcoma RMS 2005 IVADo | null | null | EW EUROEWING 2012 ARM B IE | 101340491 |
| 160016636 | 160019809 | 1.7 | 84.6 | null | 2016-07-17 | 2021-04-10 | NB HRNBL-1 COJEC Ind COURSE B | 01 | null | TRIAL | 100921383 |
| 160016640 | 160019810 | 1.74 | 71 | null | 2020-08-09 | 2020-08-15 | Ifosfamide | 02 | null | ETOPOSIDE | 100225927 |
| 160016641 | 160019811 | 1.82 | 74.9 | null | 2017-09-18 | 2018-02-10 | ETOP 13-18 BEAT-meso Trial | 01 | null | GEMCITABINE | 100119618 |
| 160016655 | 160019812 | 0 | 78.6 | null | 2019-09-04 | 2019-09-26 | Carboplatin + Liposomal Doxorubicin | 02 | N | NB BEACON TEMOZOLOMIDE ALONE | 100203446 |
| 160016706 | 160019813 | null | 73.2 | Palliative (P) | 2020-11-19 | 2020-11-21 | EW EuroEwing 2012 Arm B IE | 01 | N | VAI | 100928396 |
| 160016710 | 160019814 | 0 | 88.6 | null | 2017-02-28 | 2017-02-28 | Carboplatin + Liposomal Doxorubicin | null | null | EW EUROEWING 2012 ARM B IE | 100954690 |
| 160016712 | 160019815 | 1.78 | 89.8 | Curative (C) | 2020-09-21 | 2021-05-12 | Etoposide oral | 02 | N | EW EUROEWING 2012 ARM B VC | 100683768 |
| 160016728 | 160019816 | 1.73 | 82.4 | Curative (C) | 2020-01-31 | 2020-01-31 | Trial Unspecified | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 101189672 |
| 160016745 | 160019817 | 1.64 | 0 | Palliative (P) | 2021-09-01 | 2021-09-15 | VINCRISTINE | 02 | N | NB HRNBL-1 BUMEL MAT | 101560703 |
| 160016749 | 160019818 | 1.76 | 82 | Curative (C) | 2019-04-03 | 2019-07-22 | Etoposide + Ifosfamide + HD Mtx | 02 | N | GEMCITABINE | 100080250 |
| 160016779 | 160019819 | 1.65 | 53.6 | Curative (C) | 2021-02-02 | 2021-02-09 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | null | VINCRISTINE | 100909788 |
| 160016780 | 160019820 | 0 | 60.3 | Palliative (P) | 2016-09-13 | 2016-09-15 | Olaparib | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100363669 |
| 160016784 | 160019821 | 0 | 95.4 | Curative (C) | null | null | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | IFOSFAMIDE | 101548082 |
| 160016796 | 160019822 | 1.82 | 111.25 | Curative (C) | 2019-08-07 | 2019-10-02 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | OLARATUMAB | 101456359 |
| 160016811 | 160019823 | 1.52 | 75 | null | null | null | Cisplatin + Doxorubicin | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100428216 |
| 160016838 | 160019824 | null | 93.9 | Palliative (P) | 2016-10-24 | 2016-11-01 | WT SIOP 2002 01 post op VA | 02 | N | STS NON-RHABDO EPSSG 2005 IVA | 100101467 |
| 160016844 | 160019825 | 1.57 | 93.9 | null | 2017-03-09 | 2017-03-10 | Gemcitabine + Treosulfan (iv) | 02 | null | BORTEZOMIB + DARATUMUMAB | 100517306 |
| 160016852 | 160019826 | 1.63 | 81.25 | Palliative (P) | 2017-03-02 | 2017-03-26 | Cisplatin + Etoposide po | 02 | N | IVADO | 100332645 |
| 160016868 | 160019827 | null | 17.5 | Curative (C) | 2020-11-02 | 2020-11-10 | BLEOMYCIN | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + DOXORUBICIN + VINCRISTINE | 101197738 |
| 160016877 | 160019828 | 1.56 | 17.6 | null | 2018-03-10 | 2018-03-18 | null | 02 | null | ETOPOSIDE + IFOSFAMIDE | 100841815 |
| 160016885 | 160019829 | 1.79 | 0 | Neo-adjuvant (N) | 2020-11-19 | 2020-11-19 | null | 02 | N | OLARATUMAB | 101028116 |
| 160016889 | 160019830 | 1.8 | 118 | null | 2019-03-06 | 2019-04-18 | Bendamustine+Rituximab(Sub Courses) | 02 | null | IVA | 100828540 |
| 160016893 | 160019831 | 1.7 | 83.4 | Curative (C) | null | 2020-12-20 | Cyclophosphamide + Topotecan | 02 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 100280433 |
| 160016921 | 160019833 | 1.77 | 7.4 | 03 | 2021-10-01 | 2021-11-12 | NB HRNBL-1 COJEC Ind COURSE A | 02 | N | IPILIMUMAB + NIVOLUMAB | 100601969 |
| 160016953 | 160019834 | 1.75 | 65 | Curative (C) | 2016-04-25 | 2016-05-09 | GEMCITABINE | 02 | N | POMALIDOMIDE | 100054016 |
| 160016955 | 160019835 | 1.88 | 64.4 | null | 2019-04-24 | 2019-04-25 | EW EuroEwing 99 : VActI | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101863220 |